

# IVHEM

# 10<sup>th</sup> 2023

INTERNATIONAL  
VIRAL HEPATITIS  
ELIMINATION  
MEETING

1-2 DECEMBER 2023  
**AMSTERDAM,  
THE NETHERLANDS**



## Program Book

ame

COALITION  
FOR GLOBAL  
HEPATITIS  
ELIMINATION

[AcademicMedicalEducation.com](https://AcademicMedicalEducation.com)




Celebrating **10 Years**  
of Progress Towards the  
**Elimination of Viral Hepatitis**  
as a **Public Health Threat**



<a href="#"><u>Welcome Message</u></a>	4
<a href="#"><u>Objectives</u></a>	5
<a href="#"><u>General Information</u></a>	8
<a href="#"><u>CME Accreditation</u></a>	10
<a href="#"><u>Onsite Team</u></a>	11
<a href="#"><u>Faculty</u></a>	12
<a href="#"><u>Program</u></a>	16
<a href="#"><u>Acknowledgments</u></a>	21

# Welcome Message

## Program Chairs



**Huma Qureshi  
MD**

Pakistan Medical  
Research Council,  
Karachi, Pakistan



**John Ward  
MD**

Coalition for Global  
Hepatitis Elimination,  
Task Force for Global  
Health / Rollins  
School of Public  
Health, Emory  
University,  
United States

Dear Colleagues,

We warmly welcome you to the **International Viral Hepatitis Elimination Meeting (IVHEM) 2023**. This year is special as we celebrate the **10th anniversary of IVHEM**. Convened by Academic Medical Education and the Coalition for Global Hepatitis Elimination (CGHE), the meeting continues to be a global forum for the exchange of practical experiences for translating diagnostic and therapy advances of viral hepatitis into broad applications that accelerate progress towards the elimination of viral hepatitis as a public health threat by 2030.

Held in the last month of the year, IVHEM has become the perfect venue for reviewing new advancements, opportunities, and challenges from the previous year. 2023 has been a momentous year. Egypt was recently certified as reaching the gold tier on the path to HCV elimination. Gavi lifted its pause on hepatitis B birth dose support. China released new HBV treatment guidelines with expanded eligibility. The WHO has released new elimination guidance, additional countries have joined the UN Group of Friends to Eliminate Hepatitis, and the evidence base on simplified models of HBV and HCV care continues to grow.

At this year's IVHEM meeting, we will unpack what these milestones mean for progress towards HBV and HCV elimination, globally and locally. We will hear from leaders in countries such as Egypt, Ukraine, and Pakistan on their latest program achievements and plans. New WHO HBV guidelines and key global reports will be shared. Moreover, sessions will revisit the latest in HBV prevention strategies and explore new frontiers in diagnosis and monitoring technology and other innovations.

We hope you will join us for this year's meeting either in person or virtually. We are at a critical juncture for hepatitis elimination, and only by coming together to share data, models of care, and innovative ideas will we reach our shared HBV and HCV elimination goals.

*Best wishes,  
Huma Qureshi and John Ward*

## Meeting Objectives


This meeting aims to:

- Provide a forum for knowledge exchange and discussion of practical experiences related to the clinical management of viral hepatitis;
- Provide a toolbox for the practical application of research & development for evidence-based policymaking; and
- Facilitate cross-disciplinary discussion on barriers and challenges preventing the elimination of viral hepatitis.

## Learning Objectives

After participating in this activity, participants will be able to:

- Identify innovative strategies for hepatitis B and hepatitis C testing and linkage to care and how these can be applied to their program and clinical activities;
- Recognize the needs from a public health perspective and respond to these needs by reshaping their policymaking approaches;
- Further develop new or strengthen already existing foundations for political commitment, national planning, and program improvements; and
- Translate the latest research and technologies into clinical policy and practice for delivering an adequate continuum of viral hepatitis services.



# What Your Peers Say

**“ IVHEM Delivers high-quality expert opinions and research to guide practical implementation of hepatitis elimination ”**

**“ It was a rich exchange of experiences and best practice in HCV elimination efforts across geographical regions, and the impact was very good ”**

**“ Good emphasis on hepatitis and global health, something quite severely lacking in the top world liver meetings! ”**

**“ A very vital meeting for hepatologists across the globe and infectious disease physicians ”**

**“ Educational and practical.  
Well-organized and impactful ”**

**“ I would like to recommend this meeting to my colleagues because of the content and meaning of viral hepatitis elimination in worldwide. In addition, I describe this meeting as a very important event to share experiences and the latest knowledge in the field of viral hepatitis at local and international levels ”**

**“ Very well organized!  
Great networking opportunity ”**

**“ It was a festival of ideas toward an achievable goal for the elimination of viral hepatitis ”**

**“ Great minds coming together to achieve great things! ”**

# General Information

## Abstracts

Accepted abstracts are published in the official abstract book of the **International Viral Hepatitis Elimination Meeting (IVHEM) 2023**. The abstract book is available on the meeting's webpage.

## Badge Policy

All registered delegates are provided with an identity badge. Please wear your badge at all times to ensure admission to the meeting. No spare badges can be issued.

## Certificate of Attendance

The certificate of attendance will be sent by e-mail to participants that have successfully completed the program and filled in the post-meeting survey.

## Code of Conduct

All individuals are required to observe our Code of Conduct. We do not tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. Please report any incidents to VE and AME via [info@amededu.com](mailto:info@amededu.com) or to one of our on-site personnel. Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.



View in full:

[AcademicMedicalEducation.com/  
our-commitment-diversity-  
and-inclusion](https://www.AcademicMedicalEducation.com/our-commitment-diversity-and-inclusion)

## Meeting Language

The official language of the meeting is English.

## Enduring Materials

**ame** Webcasts of the presentations, along with the PDF presentations will be available on [www.AcademicMedicalEducation.com](http://www.AcademicMedicalEducation.com) shortly after the meeting, granted we have received the speakers' permission to do so.

## Feedback Form

Your feedback is very valuable to us and enables us to further improve this program. At the end of the meeting, a survey will be sent to you via e-mail. We would like to ask you to complete it.

## Networking Opportunities

Make use of the options to network during the coffee breaks, lunch, poster reception, and networking dinner.

The **Poster Reception** is accessible to all onsite registered delegates and is included in the registration fee. The reception takes place on **Friday, 1 December 2023 at 17:30 CET**.

The **Networking Dinner** is available to all onsite registered delegates for an additional fee. Please contact the onsite team if you would like to purchase a ticket. The dinner takes place on **Friday, 1 December 2023 at 19:00 CET**.

## Posters

During the meeting, all accepted posters are displayed in the virtual poster gallery. The poster gallery is always open for you. For those attending in-person, there will be a poster viewing session and reception at the end of day 1.

---

**Disclaimer:** This meeting aims to offer participants the opportunity to share information. Academic Medical Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Academic Medical Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.



### Social Media

We encourage you to post news and tweet about **#IVHEM #IVHEM2023** on your social media accounts during the meeting. You can either post your own tweets or retweet a message from the official [@Academic\\_MedEdu](https://twitter.com/Academic_MedEdu).

### Time Zones

Times are in Central European Time (CET). If you need to convert the times to your timezone, this website might be of interest to you: [www.WorldTimeBuddy.com](http://www.WorldTimeBuddy.com).

### Venue

**IVHEM 2023** will be held at the Amsterdam Marriott Hotel in Amsterdam, the Netherlands.

### Virtual Platform

OnAIR is the virtual platform that will be used for the **International Viral Hepatitis Elimination Meeting (IVHEM) 2023** for those attending virtually. The recordings of this meeting will be available on the virtual platform until approximately 3 weeks after the closure of the meeting.





The **International Viral Hepatitis Elimination Meeting (IVHEM) 2023**, Amsterdam, Netherlands, **01/12/2023-02/12/2023** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **7.5 European CME credits (ECMEC®s)**.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at <https://edhub.ama-assn.org/pages/applications>.

Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. College of Physicians and Surgeons of Canada.



## Your Onsite Team



**Jesper Niesen**  
Senior Project Manager  
[Jesper.Niesen@amededu.com](mailto:Jesper.Niesen@amededu.com)




**Michelle Wu**  
Project Coordinator  
[Michelle.Wu@amededu.com](mailto:Michelle.Wu@amededu.com)



**Dominika Balounová**  
Junior Project Coordinator  
[Dominika.Balounova@amededu.com](mailto:Dominika.Balounova@amededu.com)




**Michiel de Groot**  
AV Manager



**Bilal Badsı**  
AV Coordinator



**Daria Bohdanova**  
Junior Project Coordinator



## Organizing Committee



**Danjuma K. Adda**  
**MPH, FIMS, Dip-IMS**  
World Hepatitis Alliance (WHA),  
Nigeria  
[View Bio >](#)



**Graham Cooke**  
**MD, PhD**  
Imperial College London,  
United Kingdom  
[View Bio >](#)




**Manal Hamdy El-Sayed**  
**MD, PhD**  
Ain Shams University,  
Egypt  
[View Bio >](#)



**Jordan Feld**  
**MD, MPH**  
Toronto Centre for Liver Disease,  
Canada  
[View Bio >](#)




**Jessica Howell**  
**MBBS, FRACP, PhD, MSc,  
PGDip, PH**  
University of Melbourne /  
Burnet Institute, Australia  
[View Bio >](#)




**Olufunmilayo Lesi**  
**MD, MBA, FMCP**  
World Health Organization,  
Switzerland  
[View Bio >](#)



**Rosmawati Mohamed**  
**MD, MRCP, MIntMed, MBBS**  
University Malaya Medical Centre,  
Malaysia  
[View Bio >](#)



**Huma Qureshi**  
**MD**  
Pakistan Medical Research  
Council, Pakistan  
[View Bio >](#)



**Marcelo Silva**  
**MD**  
Latin American Association for  
the Study of the Liver, Austral  
University Hospital, Argentina  
[View Bio >](#)



**John Ward**  
**MD**  
Coalition for Global Hepatitis  
Elimination, Task Force for Global  
Health / Rollins School of Public  
Health, Emory University,  
United States  
[View Bio >](#)

## Scientific Committee

<b>Rakesh Aggarwal, MD (AIIMS), DM (PGIMER), FNASc, FAMS</b>	Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India
<b>Po-Lin Chan, MD</b>	World Health Organization, Philippines
<b>Gagandeep Singh Grover, MD</b>	Health and Family Welfare, India
<b>Saeed Hamid, MBBS, FRCP, FRCPI, FACP, FACG, FAASLD</b>	Aga Khan University, Pakistan
<b>Angelos Hatzakis, MD, PhD, MSc</b>	Athens University Medical School, Greece
<b>Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD</b>	Burnet Institute, Australia
<b>Khin Pyone Kyi, MBBS, DBact, MMedSc, PhD, FRCP</b>	Myanmar Liver Foundation, Myanmar
<b>Jeffrey Lazarus, PhD, MIH, MA</b>	Barcelona Institute for Global Health (ISGlobal), Spain
<b>Maud Lemoine, MD, PhD</b>	Imperial College London, United Kingdom
<b>Liudmyla Maistat</b>	Medicines Patent Pool, Switzerland
<b>Hailemichael Desalegn Mekonnen, MD, PhD</b>	St. Paul's Hospital Millennium Medical College, Ethiopia
<b>Yvonne Nartey, MBChB, MSc, MPhil</b>	Cape Coast Teaching Hospital, Ghana
<b>Michael Ninburg</b>	Hepatitis Education Project (HEP), United States
<b>Ponsiano Ocama, MD, PhD</b>	Makerere University, Uganda
<b>Jean-Michel Pawlotsky, MD, PhD</b>	Hôpital Henri Mondor, France
<b>Homie Razavi, PhD, MBA</b>	Center for Disease Analysis (CDA), United States
<b>Shiv. K. Sarin, MD, DM, DSc. (Hony.), FNA, FNAS</b>	Institute of Liver and Biliary Sciences (ILBS), India
<b>Janvier Serumondo, MD</b>	Rwanda Biomedical Centre, Rwanda
<b>Mark Sonderup, B Pharm, MBChB, FCP(SA), MMed</b>	University of Cape Town, South Africa
<b>Sonjelle Shilton, MPH</b>	Foundation for Innovative New Diagnostics (FIND), Switzerland
<b>Nasamon Wanlapakorn, MD, PhD</b>	Chulalongkorn University, Thailand

## Invited Speakers



**Danjuma K. Adda**  
**MPH, FIMS, Dip-IMS**

World Hepatitis Alliance (WHA),  
Nigeria

[View Bio >](#)



**Maria Buti**  
**MD, PhD**

Hospital General Universitari  
Valle Hebron,  
Spain

[View Bio >](#)



**Samir Desai**  
**B.Sc., MA, M Phil, Executive  
Management Program- IIM  
Ahmedabad**

Zyodus Lifesciences Limited, India

[View Bio >](#)



**Joseph Doyle**  
**MBBS BA(Hons) MPH PhD  
FRACP FAFPHM**

Monash University / Burnet Institute  
Australia

[View Bio >](#)



**Philippa Easterbrook**  
**MD, FRCP, MPH, DTM&H**

World Health Organization,  
Switzerland

[View Bio >](#)



**Jordan Feld**  
**MD, MPH**

Toronto Centre for Liver Disease,  
Canada

[View Bio >](#)



**Olga Gvozdetska**

Public Health Center of the Ministry  
of Health,  
Ukraine

[View Bio >](#)



**Mohamed Hassany**  
**M.B.BCh., M.Sc., M.D.**

National Hepatology and Tropical  
Medicine Research Institute (NHTMRI),  
Egypt

[View Bio >](#)



**Christophe Hézode**  
**MD, PhD**

Gilead Sciences,  
France

[View Bio >](#)



**Naveed Zafar Janjua**  
**MBBS, MSc, DrPH**

Centre for Disease Control / School of  
Population & Public Health, University  
of British Columbia, Canada

[View Bio >](#)



**Jidong Jia**  
**MD, PhD**

Beijing Friendship Hospital,  
China

[View Bio >](#)



**Benjamin La Brot,**  
**MD**

Roche Molecular Systems, Inc.,  
United States

[View Bio >](#)



**Olufunmilayo Lesi**  
**MD, MBA, FMCP**

World Health Organization,  
Switzerland

[View Bio >](#)



**Simbarashe Mabaya**  
**MD, MPH, EMBA**

Gavi, The Vaccine Alliance,  
Switzerland


[View Bio >](#)



**Christophe Martinaud**  
**MD, PhD**

Medical Director - Medical &  
Scientific Affairs Europe, Middle  
East & Africa, Cepheid, France

[View Bio >](#)



**Rosmawati Mohamed**  
**MD, MRCP, MIntMed, MBBS**

University Malaya Medical Centre,  
Malaysia

[View Bio >](#)



**Gibril Ndow**  
**MD, PhD**

London School of Hygiene & Tropical  
Medicine,  
United Kingdom

[View Bio >](#)



**Gamal Shiha**  
**MB BCh, M.SC, MD**

Mansoura University /  
Egyptian Liver Research Institute  
and Hospital (ELRIAH), Egypt

[View Bio >](#)



**Sonjelle Shilton**  
**MPH**

Foundation for Innovative New  
Diagnostics (FIND),  
Switzerland

[View Bio >](#)



**Huma Qureshi**  
**MD**

Pakistan Medical Research Council,  
Pakistan

[View Bio >](#)



**Osman Khalid Waheed**

Ferozsons Laboratories Limited,  
Pakistan

[View Bio >](#)



**John Ward, MD**

Coalition for Global Hepatitis  
Elimination, Task Force for Global  
Health / Rollins School of Public  
Health, Emory University,  
United States

[View Bio >](#)

## Day 1 | Friday, 1 December

Central European Time (CET)

---

1:00 PM **Opening & Welcome by Program Chairs**

**Huma Qureshi, MD**

Pakistan Medical Research Council, Pakistan

**John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

---

**Session 1: Hepatitis Elimination - Where Do We Stand?**

*Co-chairs: Danjuma Adda & John Ward*

1:15 PM **Progress Towards Hepatitis Elimination: WHO Perspective**

**Olufunmilayo Lesi, MD, MBA, FMCP**

World Health Organization, Switzerland

1:25 PM **Egypt's National Program on Hepatitis Elimination**

**Mohamed Hassany, M.B.BCh., M.Sc., M.D.**

National Hepatology and Tropical Medicine Research Institute (NHTMRI), Egypt

1:35 PM **Pakistan's National Program on Hepatitis Elimination**

**Huma Qureshi, MD**

Pakistan Medical Research Council, Pakistan

1:40 PM **Ukraine's National Program on Hepatitis Elimination**

**Olga Gvozdetska**

Public Health Center of the Ministry of Health, Ukraine

1:45 PM **Commission & Coalition Report**

**John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

---

1:55 PM **Panel Discussion on Challenges**

---

2:35 PM **Coffee Break & Poster Viewing**

---

**Session 2: New HBV Treatment Guidelines - Expanding Access to Achieve 2030 Targets**

*Co-chairs: Jessica Howell & Huma Qureshi*

3:05 PM **Update on New WHO Treatment Guidelines**

**Philippa Easterbrook, MD, FRCP, MPH, DTM&H**

World Health Organization, Switzerland



- 3:20 PM **Towards an Expanded Access: New HBV Treatment Guidelines in China**  
**Jidong Jia, MD, PhD**  
 Beijing Friendship Hospital, China
- 3:35 PM **Stigma Reducing/Elimination Program led by Community**  
**Danjuma K. Adda, MPH, FIMS, Dip-IMS**  
 World Hepatitis Alliance (WHA), Nigeria
- 3:50 PM **The Gambia's Regional Perspectives on Implementation Challenges**  
**Gibril Ndow, MD, PhD**  
 London School of Hygiene & Tropical Medicine, United Kingdom
- 3:53 PM **Spain's Regional Perspectives on Implementation Challenges**  
**Maria Buti, MD, PhD**  
 Hospital General Universitari Valle Hebron, Spain
- 3:56 PM **The Western Pacific's Regional Perspectives on Implementation Challenges**  
**Rosmawati Mohamed, MD, MRCP, MIntMed, MBBS**  
 University Malaya Medical Centre, Malaysia
- 
- 4:00 PM **Panel Discussion on Challenges**
- 
- 4:40 PM **Short Break**
- 
- Closing Lecture Day 1: When Two Epidemics Collide**  
*Chair: Olufunmilayo Lesi*
- 
- 4:55 PM **Introduction**  
**Olufunmilayo Lesi, MD, MBA, FMCP**  
 World Health Organization, Switzerland
- 5:00 PM **Reducing Harm and Integrating Care For HIV and Viral Hepatitis**  
**Joseph Doyle, MBBS BA(Hons) MPH PhD FRACP FAFPHM**  
 Monash University / Burnet Institute, Australia
- 
- 5:15 PM **Discussion**
- 
- 5:30 PM **Poster Viewing & Welcome Reception**
- 
- 7:00 PM **Networking Dinner**

## Day 2 | Saturday, 2 December

Central European Time (CET)

### Session 3: New Tools for Diagnostics & Monitoring to Tackle Long-Standing Challenges

Co-chairs: Philippa Easterbrook & Farid Ahmad

- 9:00 AM **Self-Testing for HCV: Lessons Learned from Implementation Pilots**  
**Sonjelle Shilton, MPH**  
Foundation for Innovative New Diagnostics (FIND), Switzerland
- 9:15 AM **New Biomarkers and Core Antigen-Based Tests for HBV**  
**Jordan Feld, MD, MPH**  
Toronto Centre for Liver Disease, Canada
- 9:30 AM **#1 Impact of S Gene and Prec/C Mutations on Outcome of HBV Infection**  
**Shreyasi Athalye**  
ICMR-National Institute of Immunohematology, India
- 9:40 AM **#2 Evaluation of a Commercial Real-Time Assay in Dried Blood Spot Samples for Monitoring Hepatitis C Treatment Outcome in People Who Inject Drugs in the Real World**  
**Anna Not**  
Institut d'Investigació Germans Trias i Pujol (IGTP), Spain
- 9:50 AM **#3 Free Hepatitis C Testing Using Plasma Separation Card and Linkage to HCV Care in Pakistan**  
**Huma Qureshi**  
Pakistan Medical Research Council, Pakistan

10:00 AM **Discussion**

10:20 AM **Coffee Break**

### Session 4: Prevention

Co-chairs: Jordan Feld & Naveed Janjua

- 10:45 AM **Birth Dose of HBV Vaccine**  
**Simbarashe Mabaya, MD, MPH, EMBA**  
Gavi, The Vaccine Alliance, Switzerland
- 11:00 AM **Hep D - Disease Burden, Screening, Preventing Disease Progression**  
**Maria Buti, MD, PhD**  
Hospital General Universitari Valle Hebron, Spain
- 11:15 AM **#4 Integration of Hepatitis B Screening and Management in Antenatal Services: A Comprehensive Approach to Prevent Mother-To-Child Transmission**  
**Rijimra Ande**  
Centre For Initiative And Development / Chagro Care Trust, Nigeria

11:25 AM **#5 Characterizing Individuals Who Remain to Be Screened for Hepatitis C and Those Lost to Follow-up from Georgia’s Hepatitis C Elimination Program**

**Sophia Surguladze**

The Taskforce For Global Health, Georgia

11:35 AM **#6 Hepatitis B Virus Prevalence and Implications for Vertical Transmission among Pregnant Women in Rural Communities of Taraba State - Nigeria**

**Lawrence Daniel**

Center For Initiative And Development, Nigeria

11:45 AM **Discussion**

12:00 PM **Lunch**

**Session 5: Innovations in Service Delivery**

*Co-chairs: Maria Buti & Graham Cooke*

1:00 PM **HCV Care Beyond the Cure**

**Naveed Zafar Janjua, MBBS, MSc, DrPH**

BC Centre for Disease Control / School of Population & Public Health, University of British Columbia, Canada

1:15 PM **Delivering Care in Remote Communities - Sharing a Successful Example**

**Gamal Shiha, MB BCH, M.SC, MD**

Faculty of Medicine, Mansoura University / Egyptian Liver Research Institute and Hospital (ELRIAH), Egypt

1:30 PM **#7 Assessing the Cost-Effectiveness of a Treat-All Policy Change for Hepatitis B in Six Who Regions**

**Christopher Seaman**

Burnet Institute, Australia

1:40 PM **#8 An Operational Research Roadmap to Simplify Delivery of Hepatitis B Services in Low And Middle Income Countries (LMICs)**

**Neil Gupta**

Coalition For Global Hepatitis Elimination, United States

1:50 PM **#9 Towards HCV Elimination by the End of the Decade – Optimized Approaches for Vulnerable, Inner-City Populations**

**Brian Conway**

Vancouver Infectious Diseases Centre, Canada

2:00 PM **Discussion**

## **Panel Discussion: Joining Forces to Eliminate Viral Hepatitis: How to Strengthen Collaboration?**

*Chair: John Ward*

2:20 PM **Panelist:**

**Christophe Hézode, MD, PhD**

Gilead Sciences, France

**Samir Desai, B.Sc., MA, M Phil, Executive Management Program- IIM Ahmedabad**

Zydus Lifesciences Limited, India

**Benjamin La Brot, MD**

Roche Molecular Systems, Inc., United States

**Christophe Martinaud, MD, PhD**

Medical Director - Medical & Scientific Affairs Europe, Middle East & Africa, Cepheid, France

**Osman Khalid Waheed**

Ferozsons Laboratories Limited, Pakistan

3:20 PM **Closing Remarks**

**Huma Qureshi, MD**

Pakistan Medical Research Council, Pakistan

**John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

3:30 PM **End of Meeting**

## GOLD LEVEL SPONSOR



Supported by Gilead who provided funding. Gilead has had no input into the content of the materials used at this meeting/conference.

## ENDORSERS



## MEDIA PARTNERS









**Thank you** for your  
continuous **dedication**  
**and contributions** over  
the past **10 years of**  
**IVHEM!**

Let's continue to work together to  
accelerate progress and envision a  
world free from the burdens of viral  
hepatitis in the near future!

